Your session is about to expire
← Back to Search
Dose Level 2 for Chronic Lymphocytic Leukemia
Study Summary
This trial is testing a new combination of drugs (Loncastuximab Tesirine and Aclabrutinib) for treating chronic lymphocytic leukemia. The main goal is to find
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any available positions for participants in this research study?
"Indeed, as stated on clinicaltrials.gov, this trial is currently in the active recruitment phase. It was initially posted on December 18th, 2023 and last updated on December 21st, 2023. The study aims to enroll a total of 24 patients from one location."
Has the Food and Drug Administration (FDA) granted approval for Dose Level 3?
"Based on our assessment at Power, the safety of Dose Level 3 is rated as 1. This rating is attributed to it being a Phase 1 trial with limited evidence supporting both its safety and effectiveness."
What is the total number of individuals currently under research in this clinical trial?
"Indeed, the details on clinicaltrials.gov indicate that this trial is currently in search of eligible patients. The trial was initially published on December 18th, 2023 and underwent its latest update on December 21st, 2023. A total of 24 participants will be enrolled at a single study site."
Share this study with friends
Copy Link
Messenger